APC- Adenomatous Polyp of the Colon Study- unpublished
Incidence of cardiac events
Placebo 6/679 (0.9%)
Celebrex (lo dose) 15/685 (2.2%)
Celebrex (hi dose) 20/671 (3%)

Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000;284:1247-55
A double blind, randomized controlled trial in which 8059 patients were randomized to receive 400 mg of Celecoxib twice per day, 800 mg of ibuprofen three times a day or 75 mg of diclofenac twice per day.
This study demonstrated no significant difference in cardiovascular events between Celecoxib and NSAIDs.

White WB, Faich G, Borer JS, et al. Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib. Am J Cardiol 2003;92:411-8
Meta-analysis of 15 prospectively randomized celecoxib clinical trials involving 34,771 celecoxib-treated patients.
Trials were analyzed for incidence of:
cardiovascular and unknown deaths
nonfatal myocardial infarctions
nonfatal strokes
Incidences of the analyzed events were not significantly different between the celecoxib and placebo groups, nor for the celecoxib group compared with the NSAIDs group, regardless of aspirin use and NSAID type.
These comparative analyses demonstrate no evidence of increased risk of cardiovascular thrombotic events associated with celecoxib compared with either conventional NSAIDs or placebo.

Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet - published online January 25, 2005
A total of 1,394,764 Kaiser patients contributed 2,302,029 person-years of observation time
Ibuprofen - 991,261 Celecoxib - 40,405
Naproxen - 435,492 Rofecoxib - 26,748
Controls were generally comparable for cardiovascular risk factors, although low-dose aspirin use was somewhat lower in celecoxib-exposed patients than in the other groups.
When all current users of rofecoxib were compared with remote users of NSAIDs, the risk of serious coronary heart disease was enhanced 1.34 fold.
In current users of celecoxib, a slightly reduced risk of serious coronary heart disease was noted (0.84).

Kimmel SE, Berlin JA, Reilly M, et al. Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Ann Intern Med February 1, 2005;142:157-64
1718 case-patients with a first non-fatal MI admitted to 36 hospitals in a 5-county area in PA, and 6800 controls randomly selected from the same counties.
Rofecoxib use compared to Naproxen demonstrated an increased RR of MI; RR - 3.39; CI 1.37 - 8.4.
Rofecoxib use compared to Celecoxib demonstrated an increased RR of MI; RR - 2.72; CI 1.24 - 5.95.
Celecoxib use compared to Ibuprofen demonstrated a reduced RR of MI; RR - 0.77; CI 0.40 - 1.48.
Celecoxib use compared to no drug use demonstrated a reduced RR of MI; RR - 0.43; CI 0.23 - 0.79.

Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT)
2400 people on placebo vs 400mg Celebrex vs Naproxen.
"Although no significant increase in risk for celecoxib was found in this trial, the use of these drugs in the study was suspended in part because of findings reported last week from an NCI trial to test the effectiveness of celecoxib in preventing colon cancer. In addition, however, data from the ADAPT trial indicated an apparent increase in cardiovascular and cerebrovascular events among the participants taking naproxen when compared to those on placebo."

Cyclooxygenase-2-dependent and independent effects of celecoxib in pancreatic cancer cell lines. Mol Cancer Ther 2004;3:1421-6

COX-2 inhibition as a tool to treat and prevent colorectal cancer. Crit Rev Oncol Hematol 2004;52:81-101

Role of COX-2, thromboxane A(2) synthase, and prostaglandin I(2) synthase in papillary thyroid carcinoma growth. Mod Pathol October 8, 2004 epub.

Celecoxib: a novel treatment for lung cancer. Expert Rev Anticancer Ther 2004;4:723-34

COX-2 inhibitor induces apoptosis in breast cancer cells in an in vivo model of spontaneous metastatic breast cancer. Mol Cancer Res 2004;2:1-11

Expression of cyclooxygenase-2 in adenocarcinoma of the uterine cervix and its relation to angiogenesis and tumor growth. Gynecol Oncol 2004;95:523-9

Solomon DS, McMurray JJV, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Eng J Med 2005;352:1071-80.

Drazen JM. Cox-2 inhibitors - a lesson in unexpected problems. N Engl J Med 2005;352:1131-2.